NCT05575973 - Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

October 31, 2025

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

Mitoxantrone Hydrochloride Liposome

Drug: Mitoxantrone hydrochloride liposome (20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.

DRUG

Rituximab

Drug: Rituximab (375 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.

DRUG

Lenalidomide

Drug: Lenalidomide (25 mg) will be taken orally from day 1 to day 8 of each 28-day cycle.

Trial Locations (1)

Department of Hematology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan